| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From INSERM UMR 384 (Drs. Fogli and Boespflug-Tanguy, and P. Combes and E. Eymard-Pierre), Faculté de Médecine, Clermont-Ferrand, France; Developmental and Metabolic Neurology Branch (Dr. Schiffmann and C.R. Kaneski), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Unit of Molecular Medicine and Division of Metabolic Disorders (Dr. Bertini), Bambino Gesu’ Children’s Hospital, Rome, Italy; Service d’Épidémiologie (Dr. Ughetto), Centre Hospitalier Universitaire de Clermont, Clermont-Ferrand, France; Neuropediatria (Dr. Pineda), Hospital San Joan de Deu, Barcelona, Spain; Servicio de Neurologia Infantil (Dr. Troncoso), Hospital Clinico San Borja Arriaran, Santiago, Chile; Carlo Basta Institute (Dr. Uziel), Milan, Italy; Institute of Child Health (Dr. Surtees), University College, London, UK; Neurology Department (Dr. Pugin), Geneva University Hospital, Switzerland; Service de Neurologie (Dr. Chaunu), Centre Hospitalier Universitaire de Reims, France; and Service de Neuropédiatrie (Dr. Rodriguez), Hôpital A. Trousseau, AP-HP, INSERM U546, Paris, France.
Address correspondence and reprint requests to Dr. Odile Boespflug-Tanguy, INSERM UMR 384, Faculté de Médecine, 28, place Henri Dunant BP 38, 63001 Clermont-Ferrand cedex, France; e-mail: Odile.Boespflug{at}inserm.u-clermont1.fr
Background: Recessive mutations in the five eucaryotic initiation factor 2B (eIF2B) subunits have been found in leukodystrophies of variable age at onset and severity.
Objectives: To evaluate the clinical spectrum of eIF2B-related disorders and search for a phenotype-genotype correlation.
Methods: Ninety-three individuals (78 families) with an undetermined leukodystrophy were selected on MRI-based criteria of childhood ataxia with central hypomyelination/vanishing white matter (CACH/VWM) for EIF2B genes analysis.
Results: Eighty-nine percent of individuals with MRI criteria of CACH/VWM have a mutation in one of the eIF2B beta to epsilon subunits. For 83 individuals (68 families), 46 distinct mutations (90% missense) in four of the five eIF2B subunits (beta, gamma, delta, epsilon) were identified. Sixty-four percent were in the epsilon subunit, a R113H substitution was found in 71% of eIF2B epsilon-mutated families. A large clinical spectrum was observed from rapidly fatal infantile to asymptomatic adult forms. Disease severity was correlated with age at onset (p < 0.0001) but not with the type of the mutated subunit nor with the position of the mutation within the protein. Mutations R113H in the epsilon subunit and E213G in the beta subunit were significantly associated with milder forms.
Conclusions: The degree of eIF2B dysfunction, which is involved in the regulation of protein synthesis during cellular stress, may play a role in the clinical expression of eIF2B-related disorders.
Received October 5, 2003. Accepted in final form January 28, 2004.
Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the May 11 issue to find the title link for this article.
See also pages 1464, 1503, 1598, and 1601
This article has been cited by other articles:
|
|
 |
|
  S. S. N. Wong, D. C. K. Luk, V. C. N. Wong, G. C. Scheper, and M. S. van der Knaap Vanishing White Matter Disease: The First Reported Chinese Patient J Child Neurol, June 1, 2008; 23(6): 710 - 714. [Abstract] [PDF]
|
|
|
|
|
|
J. Maletkovic, R. Schiffmann, J. R. Gorospe, E. S. Gordon, M. Mintz, E. P. Hoffman, G. Alper, D. R. Lynch, B. S. Singhal, C. Harding, et al. Genetic and Clinical Heterogeneity in eIF2B-Related Disorder J Child Neurol, February 1, 2008; 23(2): 205 - 215. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Passemard, A. Gelot, A. Fogli, S. N'Guyen, C. Barnerias, F. Niel, D. Doummar, A. S. Arbues, C. Mignot, T. B. de Villemeur, et al. PROGRESSIVE MEGALENCEPHALY DUE TO SPECIFIC EIF2B{varepsilon} MUTATIONS IN TWO UNRELATED FAMILIES Neurology, July 24, 2007; 69(4): 400 - 402. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lucas, R. Suarez, A. Marcos, F. Solano, A. Venegas, M.I. Garcia-Sanchez, L. Ortiz, and G. Izquierdo Arg113His mutation of vanishing white matter is not present in multiple sclerosis Multiple Sclerosis, April 1, 2007; 13(3): 424 - 427. [Abstract] [PDF]
|
|
|
|
 |
|
 S. J. Marciniak and D. Ron Endoplasmic reticulum stress signaling in disease. Physiol Rev, October 1, 2006; 86(4): 1133 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Federico, O. Scali, M. L. Stromillo, C. Di Perri, S. Bianchi, F. Sicurelli, N. De Stefano, A. Malandrini, and M. T. Dotti Peripheral neuropathy in vanishing white matter disease with a novel EIF2B5 mutation. Neurology, July 25, 2006; 67(2): 353 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vanderver, R. Schiffmann, M. Timmons, K. A. Kellersberger, D. Fabris, E. P. Hoffman, J. Maletkovic, and Y. Hathout Decreased Asialotransferrin in Cerebrospinal Fluid of Patients with Childhood-Onset Ataxia and Central Nervous System Hypomyelination/Vanishing White Matter Disease Clin. Chem., November 1, 2005; 51(11): 2031 - 2042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Lin, H. P. Harding, D. Ron, and B. Popko Endoplasmic reticulum stress modulates the response of myelinating oligodendrocytes to the immune cytokine interferon-{gamma} J. Cell Biol., May 23, 2005; 169(4): 603 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Kaye and H. Moser Where has all the white matter gone?: Unraveling the mysteries of leukoencephalopathies Neurology, May 11, 2004; 62(9): 1464 - 1465. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
